Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Biocryst Pharmaceuticals (BCRX) Total Non-Current Liabilities (2016 - 2019)

Biocryst Pharmaceuticals filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $128.2 million for Q3 2019.

On a quarterly basis, Total Non-Current Liabilities changed N/A to $128.2 million in Q3 2019 year-over-year; TTM through Sep 2019 was $128.2 million, a N/A change, with the full-year FY2018 number at $94.9 million, changed N/A from a year prior.
Total Non-Current Liabilities hit $128.2 million in Q3 2019 for Biocryst Pharmaceuticals, up from $121.8 million in the prior quarter.
In the past five years, Total Non-Current Liabilities ranged from a high of $128.2 million in Q3 2019 to a low of $67.9 million in Q2 2016.
Median Total Non-Current Liabilities over the past 3 years was $105.4 million (2018), compared with a mean of $102.4 million.